Reverse-transcriptase inhibitor

Transposon Announces Interim Results from a Phase 2 Study of TPN-101 for the Treatment of Progressive Supranuclear Palsy to be Presented at the AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases

Retrieved on: 
Tuesday, November 14, 2023
Alzheimer's disease, Disease, SAN, Disorder, Therapy, ALS, CSF, PSP, Biotechnology, Neurological disorder, Reverse-transcriptase inhibitor, IL-6, Patient, Conference, Frontotemporal dementia, Neuroinflammation, Progressive supranuclear palsy, Biomarker, International Conference on Creationism, Cerebrospinal fluid, Tauopathy, Transposable element, AFL, Medical imaging, Pharmaceutical industry

SAN DIEGO, Nov. 14, 2023 /PRNewswire/ -- Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases, today announced its abstract of interim results from its Phase 2 study of TPN-101 for the treatment of progressive supranuclear palsy (PSP) has been accepted for poster presentation at the hybrid AD/PD™ 2024: 18th International Conference on Alzheimer's and Parkinson's Diseases. The meeting will take place online and in Lisbon, Portugal, from March 5-9, 2024.

Key Points: 
  • In the treatment group receiving 400 mg of TPN-101 once daily for 24 weeks, TPN-101 showed an 18.4% reduction in NfL levels in CSF as compared to placebo.
  • "The lowering of CSF NfL levels seen in this interim analysis provides biomarker evidence of a treatment effect on neurodegeneration.
  • We are excited about the potential of TPN-101 as a much-needed treatment option for patients with PSP.
  • Transposon will present results from the interim analysis in a poster presentation (abstract #433) at AD/PD 2024 entitled: "A Phase 2a Study of TPN-101, a Nucleoside Reverse Transcriptase Inhibitor, in Patients with Progressive Supranuclear Palsy."

Arbutus Biopharma and Antios Therapeutics Announce Clinical Collaboration Agreement to Evaluate AB-729 in Combination with ATI-2173 in Subjects with Chronic Hepatitis B Virus Infection

Retrieved on: 
Tuesday, June 29, 2021
Medical specialties, Health, Arbutus Biopharma, Gilead Sciences, Hepatotoxins, Infectious causes of cancer, Purines, ABUS, Hepatitis B, Reverse-transcriptase inhibitor, Tenofovir disoproxil, Hepatitis

ATI-2173, AB-729 and Viread will be evaluated in combination in a single cohort in the ongoing Antios Phase 2a ANTT201 clinical trial.

Key Points: 
  • ATI-2173, AB-729 and Viread will be evaluated in combination in a single cohort in the ongoing Antios Phase 2a ANTT201 clinical trial.
  • Our collaboration with Arbutus will test that hypothesis in combination with AB-729, an RNAi drug candidate, and Viread, a nucleotide analogue.
  • The combination clinical trial cohort will include 10 subjects with chronic HBV infection assigned 8:2 to active drug (ATI-2173+AB-729) or matching placebos.
  • Arbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection.

Assembly Biosciences Presents Data from HBV Core Inhibitor Programs at the International Liver Congress™ EASL 2021

Retrieved on: 
Wednesday, June 23, 2021
Reverse-transcriptase inhibitor, Hepadnaviridae

We are pleased that the analyses of our next generation core inhibitors were selected for an oral presentation at EASL.

Key Points: 
  • We are pleased that the analyses of our next generation core inhibitors were selected for an oral presentation at EASL.
  • Overall, our data to date support our belief that core inhibitors combined with NrtI will form the backbone of finite and curative therapies for patients.
  • To date, core inhibitors have been inherently more potent against the formation of new virions (antiviral activity).
  • Sanger sequencing of HBV core and pol/RT was performed on HBV RNA for baseline samples and on HBV DNA for the first two consecutive off-treatment visits with HBV DNA >20 IU/mL.

Exavir Therapeutics announces the publication of preclinical data for the ultra-long-acting integrase inhibitor XVIR-110 in Nature Communications, affirming its unique pharmacokinetic profile and potential as a best-in-class yearly antiretroviral

Retrieved on: 
Tuesday, June 8, 2021
Hepatotoxins, Chemical substances, Medical specialties, Chemical compounds, Management of HIV/AIDS, Zidovudine, Reverse-transcriptase inhibitor, HIV, Integrase inhibitor, Rilpivirine, Discovery and development of nucleoside and nucleotide reverse-transcriptase inhibitors

The research findings, published in Nature Communications, detailed additional mechanistic, drug product stability, pharmacokinetic, and toxicology studies supporting XVIR-110s profile as a potential best-in-class once-yearly antiretroviral agent.

Key Points: 
  • The research findings, published in Nature Communications, detailed additional mechanistic, drug product stability, pharmacokinetic, and toxicology studies supporting XVIR-110s profile as a potential best-in-class once-yearly antiretroviral agent.
  • Integrase inhibitors, in addition to capsid inhibitors and nucleoside reverse transcriptase inhibitors, are a class of agents under investigation as long-acting antiretroviral therapies.
  • Preclinical pharmacokinetic and toxicology studies conducted to date support the development of XVIR-110 as a potential once-yearly antiretroviral therapeutic for HIV treatment and prevention.
  • Exavir Therapeutics is a preclinical stage biotechnology company dedicated to eliminating HIV and other viral infections with a broad modality-agnostic approach, beginning with long-acting antiretroviral therapeutics.

Inflammasome Therapeutics’ Kamuvudines May Be Answer to Preventing Blindness in Aging Population

Retrieved on: 
Monday, April 19, 2021
Other Consumer, Women, Other Health, Seniors, Other Science, Pharmaceutical, Other Technology, MEN, Research, Optical, Family, Consumer, Science, Technology, General Health, Biotechnology, AIDS, Health, Reverse-transcriptase inhibitor, Boehringer Ingelheim, Inflammasome, Boehringer, Economy of Germany, Germany

NRTIs have been in use for more than 25 years to treat HIV and Hepatitis B infections.

Key Points: 
  • NRTIs have been in use for more than 25 years to treat HIV and Hepatitis B infections.
  • Kamuvudines are slightly modified forms of NRTIs designed to avoid their toxicity, but have the same inflammasome inhibiting activity.
  • Paul Ashton, President and CEO of Inflammasome Therapeutics, the company commercially developing Kamuvudines for treatment of inflammasome-activated diseases, noted that GA currently has no approved treatment and ultimately results in blindness.
  • The company currently has collaboration agreements with Boehringer Ingelheim and the Bill & Melinda Gates Foundation.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210419005273/en/\n'

United States HIV Infection Drug Market 2021-2026: Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis

Retrieved on: 
Thursday, February 25, 2021
Branches of biology, Hepatotoxins, Biology, Reverse-transcriptase inhibitor, Management of HIV/AIDS, HIV/AIDS, Reverse transcriptase, Zidovudine, Discovery and development of nucleoside and nucleotide reverse-transcriptase inhibitors

DUBLIN, Feb. 25, 2021 /PRNewswire/ -- The "US HIV Infection Drug Market, Dosage, Price, Sales Insight 2021 - 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 25, 2021 /PRNewswire/ -- The "US HIV Infection Drug Market, Dosage, Price, Sales Insight 2021 - 2026" report has been added to ResearchAndMarkets.com's offering.
  • The research report prepared delivers insight for the US HIV drug market, which includes the growth areas as well as the channel perspective.
  • The US HIV drug market will exceed billion dollars by the next few years at exponential compound annual growth rate.
  • US Nucleoside Reverse Transcriptase Inhibitors (NRTIs) - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis

Global Antiretroviral Therapy Market Outlook to 2024, Featuring Company Profiles of Key Players Gilead Sciences, GSK, Roche Holding, Boehringer Ingelheim, Cipla and Abbvie

Retrieved on: 
Thursday, January 21, 2021
Hepatotoxins, Drugs, Prevention of HIV/AIDS, Integrase inhibitors, Management of HIV/AIDS, Protease inhibitor, Reverse-transcriptase inhibitor, Cipla, Health care, Boehringer Ingelheim, Zidovudine, Health

The global antiretroviral therapy market is anticipated to reach US$ 35.14 billion in 2024.

Key Points: 
  • The global antiretroviral therapy market is anticipated to reach US$ 35.14 billion in 2024.
  • The global antiretroviral therapy market is also prone to certain challenges like increasing voluntary male circumcisions and the huge cost of treatment.
  • The global antiretroviral therapy market by drug type can be segmented into the following: NRTI, NNRTI, protease inhibitors and integrase inhibitors.
  • The competitive landscape of the market, along with the company profiles of leading players (Gilead Sciences, GSK, Roche Holding, Boehringer Ingelheim, Cipla and Abbvie) are also presented in detail.

Global HIV Drugs Market (2020 to 2027) - by Medication Class, Non-nucleoside Reverse Transcriptase Inhibitors and HIV Integrase Strand Transfer Inhibitors - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 19, 2021
Health, Pharmaceutical, Branches of biology, Antiretroviral drugs, HIV/AIDS, Hepatotoxins, Integrase inhibitors, Reverse-transcriptase inhibitor, Management of HIV/AIDS, Reverse transcriptase, HIV, Protease inhibitor, ViiV Healthcare, Discovery and development of nucleoside and nucleotide reverse-transcriptase inhibitors

The "Global HIV Drugs Market By Medication Class, Non-nucleoside Reverse Transcriptase Inhibitors and HIV Integrase Strand Transfer Inhibitors: Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global HIV Drugs Market By Medication Class, Non-nucleoside Reverse Transcriptase Inhibitors and HIV Integrase Strand Transfer Inhibitors: Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global HIV drugs market is bifurcated into medication class and region.
  • On the basis of medication class, the market is classified into multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non Onucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), entry inhibitors, and HIV integrase strand transfer inhibitors.
  • The key market players and their strategies have been analyzed to understand the competitive outlook of the market.

Global Hepatitis B Market Spotlight Report 2020: Aligos Deals Separately Target COVID-19, Hepatitis B - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 8, 2020
Health, Other Health, RTT, Medical specialties, Clinical medicine, Infectious diseases, Antivirals, Infectious causes of cancer, Cytokines, Interferon, Hepatitis B, Hepatitis, Reverse-transcriptase inhibitor, Antiviral drug

The "Market Spotlight: Hepatitis B" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Spotlight: Hepatitis B" report has been added to ResearchAndMarkets.com's offering.
  • Marketed drugs for hepatitis B focus on targets such as DNA polymerase, reverse transcriptase, cell membrane, T lymphocytes, interferon receptor, interferon-alpha, and the immune system.
  • China leads in terms of the number of hepatitis B clinical trials globally, while Germany leads the major European markets.
  • GlaxoSmithKline leads industry sponsors with by far the highest overall number of clinical trials for hepatitis B, followed by Gilead.

ViiV Healthcare Announces Availability of CABENUVA and VOCABRIA in Canada

Retrieved on: 
Wednesday, September 23, 2020
Chemical compounds, Non-nucleoside reverse transcriptase inhibitors, Integrase inhibitors, Nitriles, Pyrimidines, Organic compounds, Drugs, Rilpivirine, Prevention of HIV/AIDS, ViiV Healthcare, Reverse-transcriptase inhibitor, Cabotegravir

LAVAL, QC, Sept. 23, 2020 /CNW/ - Today, ViiV Healthcare Canada announced stock availability of CABENUVA and VOCABRIA across the country.

Key Points: 
  • LAVAL, QC, Sept. 23, 2020 /CNW/ - Today, ViiV Healthcare Canada announced stock availability of CABENUVA and VOCABRIA across the country.
  • It combines the integrase strand transfer inhibitor (INSTI)cabotegravir with the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine.1[VOCABRIA and CABENUVA PM p4A,26A]
    Both CABENUVA and VOCABRIA received approval from Health Canada on March 18, 2020.
  • VOCABRIA, oral cabotegravir, together with Janssen Pharmaceutical Companies of Johnson & Johnson's EDURANT, oral rilpivirine, is used for the short-term treatment of HIV-1 infection in adults who are virologically stable and suppressed prior to initiating CABENUVA.1 [VOCABRIA and CABENUVA PM p4A]
    Dacia Hibbert, General Manager of ViiV Healthcare Canada, said: "We are proud to make CABENUVA and VOCABRIA available to people living with HIV.
  • Prior to initiating treatment with CABENUVA, oral dosing of VOCABRIA and EDURANT was administered for approximately one month to assess the tolerability of cabotegravir and rilpivirine.